Human iron(II)- and 2-(oxo)glutarate-dependent (Fe/2OG) dioxygenases catalyze hydroxylation of inactivated aliphatic carbon centers in reactions that are fundamentally important to central life processes (e.g., metabolism and its regulation, transcription, epigenetic inheritance) and relevant to several diseases. Plant, fungi, and bacteria have diversified the Fe/2OG structural and functional platform, using it for a bewildering array of oxidative transformations that include halogenations, dehydrogenations, cyclizations and stereoinversions of aliphatic carbon centers. As the biosynthetic machinery generating a large number of important natural-product drugs are replete with such Fe/2OG oxygenases, a predictive understanding of the reaction mechanisms and how the individual enzymes direct them could enable re-purposing of the enzymes and pathways for tailor-made drug compounds. Having recently made great progress toward understanding the hydroxylation, halogenation, and stereoinversion outcomes, we turn in this project to two of the least well- understood reaction types mediated by members of this enzyme family: oxacycle-installing 1,3- and 1,5- dehydrogenation (oxacyclization) and olefin-installing 1,2-dehydrogenation (desaturation) reactions on the pathways to the antibiotics clavulanic acid and napthyridomycin, the anesthetic scopolamine, and insecticide, norloline. We will elucidate the structures and mechanisms of the enzymes catalyzing these enigmatic reactions to develop an integrated understanding of the chemistry of this important enzyme family.

Public Health Relevance

Iron- and 2-(oxo)glutarate-dependent oxygenase enzymes from plants, fungi, and soil bacteria carry out a bewildering array of oxidative transformations in biochemical pathways to many important natural-product drugs. Most of the reactions are not in the repertoire of synthetic chemists. The precise and predictive understanding of how these enzymes promote their varied outcomes sought in this project would enable rational repurposing of these enzymes and pathways to make new drug compounds with new and improved bioactivities.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM113106-04
Application #
9513013
Study Section
Macromolecular Structure and Function A Study Section (MSFA)
Program Officer
Anderson, Vernon
Project Start
2015-09-10
Project End
2019-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
003403953
City
University Park
State
PA
Country
United States
Zip Code
16802